ALIM Share Price

Open 1.43 Change Price %
High 1.46 1 Day -0.04 -2.78
Low 1.37 1 Week -0.07 -4.76
Close 1.40 1 Month -0.05 -3.45
Volume 129774 1 Year -0.17 -10.83
52 Week High 1.72
52 Week Low 1.03
ALIM Important Levels
Resistance 2 1.48
Resistance 1 1.45
Pivot 1.41
Support 1 1.35
Support 2 1.32
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DCTH 0.13 -13.33%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
ARCI 1.45 137.70%
FALC 0.40 60.00%
AMCF 0.03 50.00%
LOCM 0.09 50.00%
OPXAW 0.10 42.86%
VRTA 4.50 38.46%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Alimera Sciences, Inc. (NASDAQ: ALIM)

ALIM Technical Analysis 1.5
As on 21st Aug 2017 ALIM Share Price closed @ 1.40 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.35 & Sell for SHORT-TERM with Stoploss of 1.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALIM Target for August
1st Target up-side 1.61
2nd Target up-side 1.74
3rd Target up-side 1.86
1st Target down-side 1.27
2nd Target down-side 1.14
3rd Target down-side 1.02
ALIM Other Details
Segment EQ
Market Capital 74180568.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.alimerasciences.com
ALIM Address
ALIM
6120 Windward Parkway
Suite 290
Alpharetta, GA 30005
United States
Phone: 678-990-5740
Fax: 678-990-5744
ALIM Latest News
Interactive Technical Analysis Chart Alimera Sciences, Inc. ( ALIM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Alimera Sciences, Inc.
ALIM Business Profile
Alimera Sciences, Inc. (Alimera), incorporated on June 4, 2003, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is focused on diseases affecting the back of the eye, or retina. The Company's product candidate is ILUVIEN. ILUVIEN is inserted in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. ILUVIEN is also being studied in three Phase 2 clinical trials for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD and retinal vein occlusion (RVO). The Company's product candidate, ILUVIEN, is an intravitreal implant providing a therapeutic effect for up to 36 months in the treatment of vision impairment associated with diabetic macular edema (DME) by delivering sustained sub-microgram levels of Fluocinolone acetonide (FAc), which is a non-proprietary corticosteroid. FAc is an active compound in ILUVIEN and a member of the class of steroids known as corticosteroids. ILUVIEN consists of a tiny polyimide tube with a membrane cap, licensed by the Company from pSivida US, Inc. (pSivida).